Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The study evaluates the efficacy and tolerability of an intensified induction and
consolidation therapy in combination with rituximab in CD20 positive standard risk patients.
Thereafter patients receive additional consolidation and reinduction cycles combined with
rituximab. In parallel minimal residual disease is evaluated. After six months and one year
the decision on intensification or discontinuation of therapy is made based on results of MRD
evaluation